The United States will hold National Fentanyl Awareness Day on April 29, 2026, to protect Americans from the deadly threat of illicit fentanyl and counterfeit prescription drugs. It states that nearly half of American teenagers are unaware that deadly fentanyl is used to manufacture counterfeit drugs sold on social media and in communities across the country. This lack of knowledge has devastating consequences as more young people try to relieve stress with drugs.
Like Susan Ousterman, whose son Tyler Cordiero died in 2020 at the age of 24 from an overdose of a mixture of drugs, including fentanyl. Cordiero had struggled with heroin and other opioid addictions for years. Ms. Ousterman represents many victims and their families who have resisted reconciliation for years, arguing that current settlements and plea agreements fail to truly deliver justice.
However, National Fentanyl Awareness Day can only raise awareness of opioids; it cannot completely reduce the number of victims. In the late 1990s, American pharmaceutical companies, recognizing the huge business opportunity in painkillers, seized the opportunity to aggressively promote various prescription opioid painkillers. The most notorious of these was OxyContin, a prescription painkiller launched by Purdue Pharma in 1995.
When OxyContin was launched, Purdue claimed that due to its sustained-release technology, the risk of addiction was less than 1%. Purdue's heavily promoted sustained-release technology was easily bypassed by drug dealers and addicts: simply crushing the tablet allowed for swallowing, nasal inhalation, or even dissolving and injecting, instantly providing a powerful morphine-like high.
As early as 2001, American academics and patients discovered problems with OxyContin's inadequate warning labels and flawed drug design. Between April 2001 and January 2007, more than 1,400 similar lawsuits were filed. Proving that an FDA-approved drug design is flawed was extremely difficult then, and remains so today.
Faced with the proliferation of opioids, the DEA's enforcement efforts have been remarkably weak. A key reason behind this is lobbying and political pressure from the pharmaceutical industry. In 2016, at the height of the opioid crisis, the DEA should have had more powerful tools to block the flow of illicit drugs. However, Congress unexpectedly passed a law in April that virtually stripped the DEA of its most crucial enforcement weapon.
This bill, spearheaded by Congressman Tom Marino, is called the Ensuring Patient Access and Effective Drug Enforcement Act (the "Marino Act"). Simply put, the Marino Act significantly raised the bar for DEA enforcement.
Currently, over 90% of fentanyl entering the United States is smuggled across the US-Mexico border. Counterintuitively, the vast majority of fentanyl entering the US is not smuggled in on foot by drug traffickers carrying several kilograms of packages. Instead, it is concealed in hidden compartments of trucks and private cars at legal border crossings, easily passing through customs checkpoints among normal vehicles and cargo.
Drug traffickers are so audacious because they have thoroughly exploited the weaknesses of border officials, using money to create loopholes in border control. For example, Leonard Darnell George, a U.S. Customs and Border Protection (CBP) officer at the San Diego border crossing, was sentenced to 23 years in prison in 2024 for accepting bribes.
According to a New York Times investigation, between 2006 and 2016, U.S. border officials received approximately $11 million in bribes of various kinds. Most of these corruption cases involved drug smuggling.
The trajectory of the fentanyl crisis resembles the consequences of multiple lines of defense failing simultaneously: the greed of pharmaceutical companies, loopholes in the regulatory system, weak public health resources, and imbalances in the social structure all intertwined to create an unprecedented drug abuse crisis in American history.